BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32938354)

  • 1. Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present).
    Fan Y; Hou X; Fang H
    Recent Pat Anticancer Drug Discov; 2020; 15(4):306-320. PubMed ID: 32938354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mcl-1 inhibitors: a patent review.
    Chen L; Fletcher S
    Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCL-1 inhibitors - where are we now (2019)?
    Fletcher S
    Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of Mcl-1 inhibitors for cancer therapy.
    Negi A; Murphy PV
    Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
    Zhu PJ; Yu ZZ; You QD; Jiang ZY
    Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An updated patent review of Mcl-1 inhibitors (2020-2022).
    Liu J; Yin F; Wang Z; Song T; Zhang Z
    Expert Opin Ther Pat; 2023; 33(5):371-383. PubMed ID: 37293764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule Mcl-1 inhibitors for the treatment of cancer.
    Belmar J; Fesik SW
    Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
    Wan Y; Dai N; Tang Z; Fang H
    Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
    Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
    Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
    Hird AW; Tron AE
    Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
    Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
    J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.
    Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R
    ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
    Beekman AM; O'Connell MA; Howell LA
    ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors.
    Du J; Liu L; Liu B; Yang J; Hou X; Yu J; Fang H
    Future Med Chem; 2020 Jul; 12(14):1293-1304. PubMed ID: 32397829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.